ASX:ACR Acrux (ACR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acrux Stock (ASX:ACR) 30 days 90 days 365 days Advanced Chart Get Acrux alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume4,000 shsAverage VolumeN/AMarket CapitalizationA$12.47 millionP/E RatioN/ADividend Yield11.66%Price TargetN/AConsensus RatingN/A Company Overview Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia. Read More Receive ACR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter. Email Address ACR Stock News HeadlinesAcrux Limited Sees Change in Substantial ShareholdingJune 30, 2025 | tipranks.comTop hiking boots for exploring trails while keeping your feet dryMay 20, 2025 | msn.comPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.July 4 at 2:00 AM | Crypto Swap Profits (Ad)Acrux Limited Announces Registry Office RelocationApril 8, 2025 | tipranks.comAcrux Limited Announces Quotation of New Securities on ASXApril 3, 2025 | tipranks.comAcrux Secures $1.73 Million Advance on R&D Tax IncentiveApril 2, 2025 | tipranks.comSouth African group buys Cononish gold mineMarch 13, 2025 | uk.finance.yahoo.comAcrux Limited Reports Significant Revenue Decline and Increased LossesFebruary 25, 2025 | tipranks.comSee More Headlines ACR Stock Analysis - Frequently Asked Questions How were Acrux's earnings last quarter? Acrux Limited (ASX:ACR) posted its earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. Acrux had a negative net margin of 113.93% and a negative trailing twelve-month return on equity of 130.13%. What other stocks do shareholders of Acrux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN). Company Calendar Last Earnings2/21/2019Today7/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolASX:ACR CIKN/A Webwww.acrux.com.au Phone+61-3-83790100FaxN/AEmployees2,018Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$5.80 million Net Margins-113.93% Pretax MarginN/A Return on Equity-130.13% Return on Assets-48.18% Debt Debt-to-Equity Ratio113.06 Current Ratio1.61 Quick Ratio2.89 Sales & Book Value Annual SalesA$5.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.57 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares290,720,000Free FloatN/AMarket CapA$12.47 million OptionableNot Optionable Beta1.21 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (ASX:ACR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrux Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.